30
Mar
2017

Third Rock’s Tango Gets $55M for CRISPR-Enabled Synthetic Lethal Cancer Combos

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Third Rock Raises $1.1B Fund, Sticks With Its Knitting in a Downturn
MOMA Gets $150M to Make Small Molecules Against ATPases, Laborers of the Cell
Third Rock-Backed Abata Secures $95M for T-reg Cell Therapy Against MS
Third Rock and Friends Bet $110M On Thrive, a Hopkins-Inspired Cancer Screening Startup